Novartis' Radioligand Therapy Lutathera Could Soon Face Generic Competition
Novartis’s Lutathera, the first FDA‑approved radioligand therapy for neuroendocrine tumors, recorded $1.5 billion in 2023 sales and dominates a market projected to exceed $3 billion by 2028. A generic version filed by Sandoz aims for a 2025 launch, marking the first non‑brand entrant in a field long controlled by Novartis. The upcoming competition could compress pricing and reshape reimbursement dynamics. Analysts see this as a pivotal moment that may accelerate innovation and broaden patient access to targeted radionuclide treatments.
FDA Approves Dupilumab for Young Children With Uncontrolled CSU
The FDA has approved dupilumab (Dupixent) for children ages 2‑11 with uncontrolled chronic spontaneous urticaria (CSU), marking the first biologic therapy for this pediatric group. The decision is based on the LIBERTY‑CUPID phase 3 program, which demonstrated significant reductions in itch...
FDA Approval of Regeneron’s Hearing Loss Gene Therapy Breaks Barriers
Regeneron Pharmaceuticals received FDA approval for Otarmeni, the first gene therapy targeting congenital deafness caused by otoferlin deficiency. The treatment, approved under the Commissioner’s National Priority Voucher program, demonstrated clinically meaningful hearing gains in 11 of 12 patients in the...
Drug-Coated Balloons Reduce the Need for Permanent Heart Stents
A sub‑study of the SELUTION DeNovo trial presented at the SCAI 2026 meeting shows that a sirolimus‑eluting balloon (SEB) can treat NSTEMI and unstable angina with outcomes comparable to drug‑eluting stents (DES). The analysis of 1,089 patients found one‑year target‑vessel...
Pugs and Frenchies Could Find Breathing Relief for Squishy Faces with New Treatment
After 15 years of research, RMIT scientists and biotech firm Snoretox have developed Snoretox-1, an injectable treatment that uses a modified tetanus toxin to improve muscle tone in the geniohyoid muscle of flat‑faced dogs. In a small clinical trial, six...
GLP-1 Drugs Target the Roots of Dementia
A systematic review of 30 preclinical studies finds that GLP‑1 receptor agonists—particularly liraglutide, semaglutide, dulaglutide and exenatide—consistently reduce amyloid‑beta plaques and tau tangles, the hallmarks of Alzheimer’s disease. The drugs also appear to curb neuroinflammation and improve brain insulin signaling,...
Tirzepatide Significantly Reduces Cardiovascular Risk in High-Risk Patients
Two recent real‑world studies demonstrate that tirzepatide, a dual GIP/GLP‑1 receptor agonist, markedly lowers cardiovascular risk in high‑risk patients. In a propensity‑matched cohort of 1,281 type‑2 diabetics undergoing percutaneous coronary intervention, tirzepatide reduced mortality by 62% and cut major adverse...
STAT+: Legislatures in Colorado and Virginia Resist Moves to Constrain Drug Affordability Boards
Legislators in Virginia and Colorado pushed back against attempts to limit the authority of state drug‑affordability boards. In Virginia, the General Assembly voted unanimously to keep the original bills that would create a board with power to set price caps...
Roche Launches New Elevidys Trial to Address EU Rejection in Duchenne Therapy Bid
Roche has launched a new global phase 3 trial of its Duchenne muscular dystrophy gene therapy Elevidys, targeting ambulatory boys after the European Medicines Agency rejected its earlier submission. The study will enroll about 100 patients and compare Elevidys to...
New ADC Yields Encouraging Clinical Benefit in Platinum-Resistant Ovarian Cancer
In a Phase I trial presented at AACR 2026, the investigational antibody‑drug conjugate QLS5132 demonstrated notable antitumor activity in patients with advanced platinum‑resistant ovarian cancer. Among 28 heavily pretreated participants, the overall objective response rate was 50% and disease control...
STAT+: Sanofi Research Priorities in Flux as New CEO Logs In
Sanofi’s new chief executive, Belén Garijo, assumes leadership amid questions about the French drugmaker’s research direction. The company recently intensified its immunology portfolio, but recent trial disappointments have dampened expectations. Garijo is expected to reassess R&D allocations, potentially shifting focus...
Roche, Facing Biosimilar Threats, Puts Faith in New Cancer and Obesity Drugs
Roche said its emerging breast‑cancer pill giredestrant and a suite of obesity drugs could generate up to $9 billion in peak annual sales. First‑quarter sales rose 6% to 14.7 billion Swiss francs (≈$18.8 billion) but fell 5% on currency effects, and the company...
Biossil Exits Stealth with $70 Million USD to Give Failed Medicines a Second Chance
Toronto‑based biotech Biossil has emerged from stealth after raising roughly $70 million in equity from investors including OpenAI and Founders Fund. The company leverages an AI platform to spot abandoned drug candidates, then licenses or purchases them to fast‑track development. It...
Drug Trials Snapshot: NUZOLVENCE
Entasis Therapeutics received FDA approval on Dec 12 2025 for NUZOLVENCE, a single‑dose oral granule treatment for uncomplicated urogenital gonorrhea in patients aged 12 and older. The approval is based on a phase 3, open‑label, non‑inferiority trial of 930 participants across five countries,...
GE HealthCare: First Patient Dosed in Trial for Manganese-Based MRI Contrast Agent
GE HealthCare announced that the first patient was dosed in the international Phase 2/3 LUMINA trial of its manganese‑based MRI contrast agent, mangaciclanol, at the Mayo Clinic. The agent has earned FDA Fast Track designation for adults and children aged two...
BBOT Shakes up Leadership as RAS Competitors Get More Visibility
BridgeBio Oncology Therapeutics (BBOT) dismissed CEO Eli Wallace and promoted CSO Pedro Beltrán to chief executive as the board seeks faster progress on its RAS‑focused pipeline. Shares, already down 18% to $8.76, slipped further after the announcement. The board also...
Trump Administration Eases Rules on some Marijuana Categories. Here's What to Know
The Trump administration announced that medical marijuana will be moved from Schedule I to Schedule III, placing it alongside substances such as codeine. The change applies only to FDA‑approved products and those sold under state medical licenses, leaving recreational cannabis untouched. By...
Kurma Partners Closes €215 Million Biofund IV to Back European BioTech Ventures From Paris
Kurma Partners announced the final close of Biofund IV at €215 million (about $232 million), a 35% increase over its €160 million (≈$173 million) predecessor. The fund, backed by pharmaceutical giant CSL, the European Investment Fund and Bpifrance, aims to make roughly twenty investments in...
Novo's Pill for Kids; Altimmune’s $225M Offering; Merck Teams with Google Cloud
Novo Nordisk reported that its oral GLP‑1 drug Rybelsus reduced hemoglobin A1C by 0.83% in adolescents aged 10‑17 with type‑2 diabetes after about six months of treatment. The result marks the first pediatric efficacy data for a GLP‑1 pill, expanding...
Amneal to Buy a Biosimilar Company; Samsung Bio Workers Protest
Amneal Pharmaceuticals announced it will acquire biosimilar developer Alvotech for an upfront $375 million, with additional contingent payments tied to regulatory milestones. The deal expands Amneal’s pipeline into high‑margin biologics, adding several approved and late‑stage biosimilar candidates. Concurrently, workers at Samsung...
Sanofi Defends Dupixent Patents, but Execs Insist It Has Nothing to Do with CEO Change
Sanofi’s interim leadership used its Q1 earnings call to reaffirm a robust patent shield for Dupixent, extending protection through 2045 despite the drug’s looming loss of exclusivity. The biologic delivered $4.9 billion in quarterly sales, a 31% increase, and remains the...
STAT+: Pharmalittle: We’re Reading About Cheap Telehealth Visits, Pharma Withholding Meds in Europe, and More
Health policy experts are flagging large fees that telehealth platforms receive from pharmaceutical companies, warning that such payments may breach federal anti‑kickback statutes and encourage overprescribing of costly brand drugs. At the same time, U.S. Health and Human Services Secretary...
Compounding Risk Alerts
The FDA continues to issue Compounding Risk Alerts to protect patients from unsafe, ineffective, or low‑quality compounded medicines. Recent alerts include potential safety risks from topical finasteride (April 22, 2025), dosing errors in injectable semaglutide (July 26, 2024), and adverse reactions linked to sulfite‑containing...
Donald Trump Is Giving Psychedelic Medicines a Welcome Boost
President Donald Trump signed an executive order on April 18, 2026, after a text from podcaster Joe Rogan highlighted ibogaine’s potential for opioid addiction. The order directs the FDA to issue priority review vouchers for selected psychedelic drugs and earmarks new...
HHS, Industry Leaders Spar over Drug Pricing, TrumpRx and PBMs
At a Politico‑hosted summit, U.S. health officials and pharma leaders clashed over the most‑favored‑nation (MFN) drug‑pricing policy championed by the Trump administration. The MFN proposal would force manufacturers to price drugs in the United States at levels comparable to lower‑cost...
Roche Insists Amylin Obesity Drug Still Valuable for Patients Who ‘Don’t Want Side Effects’
Roche defended its amylin‑based obesity drug petrelintide after Phase 2 ZUPREME‑1 data showed a 9% placebo‑adjusted weight loss over 42 weeks, falling short of analyst expectations of 12% and the 16% seen with Eli Lilly’s eloralintide. The study highlighted petrelintide’s strong tolerability,...
AAN 2026: J&J, Kyverna, Capricor and Praxis Showcase Practice-Changing Data
At the 2026 American Academy of Neurology meeting, Johnson & Johnson reported two‑year Phase 3 data showing its FcRn blocker Imaavy sustained symptom improvement and allowed most patients to cut corticosteroid use. Kyverna Therapeutics presented Phase 2 results for its CAR‑T therapy...
DemeRx Reports the US FDA IND Application Acceptance to Advance DMX-1001 for Alcohol Use Disorder
DemeRx announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for DMX-1001, an oral formulation of noribogaine, to treat alcohol use disorder (AUD). The company recently completed a multiple‑ascending‑dose (MAD) trial in healthy...
Regeneron and Sanofi Report the US FDA Approval of Dupixent (Dupilumab) for Chronic Spontaneous Urticaria (CSU)
Regeneron and Sanofi announced that the U.S. Food and Drug Administration has approved Dupixent (dupilumab) for chronic spontaneous urticaria (CSU) in patients as young as two years old who remain symptomatic despite H1 antihistamines. The decision is based on two...
STAT+: Can Erasca Be Biotech’s Next Big Thing? We’ll See
Erasca, a biotech startup valued at roughly $7 billion, is developing ERAS‑0015, a pan‑RAS inhibitor aimed at treating pancreatic cancer. The company positions itself as a cost‑effective alternative to RevMed, whose market cap exceeds $30 billion after reporting a 13.2‑month median overall...
Life Invisible
The Guardian documentary "Life Invisible" follows Chilean microbiologist Cristina Dorador as she hunts for novel microbes in the Atacama Desert to combat rising antibiotic resistance. The film underscores that resistant infections could cause 39 million deaths worldwide between 2024 and 2050....
AbbVie Opts for North Carolina to House $1.4bn Manufacturing Site
AbbVie announced a $1.4 bn investment to build a new 185‑acre manufacturing campus in North Carolina, the largest single‑site spend in the company’s history. The facility will produce oncology, immunology and neuroscience therapies and incorporate AI‑driven advanced manufacturing technologies. Construction is...
Novo Nordisk’s Oral Semaglutide Demonstrates Potential to Be the First Oral GLP-1 RA Therapy for Children and Adolescents with Type...
Novo Nordisk reported positive topline results from the phase 3a PIONEER TEENS trial, the first study of an oral GLP‑1 receptor agonist in children and adolescents with type 2 diabetes. Oral semaglutide lowered HbA1c by 0.83 percentage points versus placebo...
Merck Partners with Google Cloud in ~$1B Deal to Build AI-Enabled Enterprise Platform
Merck has signed a multi‑year agreement with Google Cloud valued at up to $1 billion to build an AI‑driven, agentic enterprise platform covering research, manufacturing, commercial and corporate functions. The collaboration will embed Google’s Gemini Enterprise and other generative AI tools...
Operational Lessons From Global Nephrology Trials
The article outlines four operational lessons drawn from the surge of global nephrology trials, noting that GlobalData tracks 888 CKD studies with only 56 multinational efforts. It argues that traditional site selection in Europe and the U.S. limits enrollment speed...
ModeX Starts Dosing in MDX2003 Trial for B-Cell Lymphoma
ModeX Therapeutics, an OPKO Health subsidiary, has begun dosing the first patients in the MDX‑2003‑101 trial of its tetraspecific T‑cell engager MDX2003 for relapsed or refractory B‑cell lymphoma. The study will evaluate tolerability, pharmacokinetics, safety and immune activity across dose‑escalation...
Epitopea Wins UK Approval for Therapeutic Vaccine Trial
Epitopea secured UK regulator and ethics committee clearance to launch OVACT, a Phase I/Ib first‑in‑human trial of its RNA‑based vaccine CryptiVax‑1001 in advanced high‑grade serous ovarian cancer. The study will evaluate safety, tolerability, immunogenicity and early clinical activity in HRP⁺/BRCA‑wildtype...
AstraZeneca Reports the P-III (I CAN) Trial Data on Ultomiris for IgA Nephropathy
AstraZeneca announced interim Phase III (I CAN) data for Ultomiris in IgA nephropathy, enrolling about 510 high‑risk adults. The trial met its primary endpoint, showing a roughly 30% reduction in 24‑hour proteinuria at 34 weeks, with benefits evident as early as 10...
ViewsML Closes Funding Round to Accelerate Commercialization of AI-Driven Virtual Biomarker Staining Platform
ViewsML announced an oversubscribed $4.9 million seed round led by Wittington Ventures, with new investors Mayo Clinic and Continuum Health Ventures joining repeat backers. The capital will fast‑track commercialization of its AI‑driven virtual biomarker staining platform, which extracts per‑cell biomarker insights...
FMRI-Based Mega-Study of Psychedelics Reveals Patterns of Brain Signaling Reorganization
An international consortium analyzed resting‑state fMRI scans from over 250 healthy volunteers who received psilocybin, LSD, DMT, mescaline or ayahuasca, creating the largest pooled dataset of psychedelic brain imaging to date. Using a unified processing pipeline and Bayesian hierarchical modeling,...
Muons, Massive Waves and Restored Sight: The Winners at the ‘Oscars of Science’ – Podcast
The Breakthrough Prize, dubbed the "Oscars of science," handed out $3 million awards in physics, mathematics and life sciences at a high‑profile ceremony in Los Angeles. Jean Bennett was among the laureates, receiving the life‑sciences prize for co‑creating the first FDA‑approved gene‑augmented...
Accelerating Drug Discovery with Fragment Screening
Scientists at DOE’s Brookhaven National Laboratory are piloting a publicly‑available fragment‑based drug design (FBDD) platform at the NSLS‑II synchrotron. Using macromolecular X‑ray crystallography, the program couples robotics, automation and AI to screen small chemical fragments against protein targets. Early tests...
Perth Biotech at Cutting Edge of the Future of Medicine
Syngenis, a Perth‑based biotech, is converting its research‑grade oligonucleotide lab into Australia’s first GMP‑certified facility, enabling local production of clinical‑grade DNA and RNA strands. The move could bring back roughly AUD 160 million (about US 105 million) of annual overseas GMP work, tapping into...
US Health Secretary Kennedy Defends Trump’s Mathematically Impossible Drug Discount Claims
U.S. Health Secretary Robert F. Kennedy Jr. defended President Donald Trump’s mathematically impossible drug‑discount claims during a Senate Finance Committee hearing, insisting a drop from $600 (≈ $566 USD) to $10 represented a 600% reduction. The assertion contradicts basic percentage math, as the actual discount...
NSW Opens $96M RNA Research and Manufacturing Facility
New South Wales has launched a $96 million (≈$63 million USD) RNA research and manufacturing hub at Macquarie University’s Innovation Precinct. The state‑run facility, operated by Aurora Biosynthetics, will produce RNA‑based vaccines and therapeutics from a single site. NSW pledged an additional...
Researchers Explore New Approach to Multivirus Drug Development
Researchers at Stanford Medicine, led by Shirit Einav, are pioneering a host‑targeted antiviral strategy that disables human enzymes essential for viral replication rather than attacking the virus directly. Their recent Nature Communications paper describes a small‑molecule, RMC‑113, which halted replication...
Chicken Gene-Editing Advance Opens Path to Drug-Producing Eggs
University of Missouri researchers used CRISPR to insert a gene cassette into the chicken housekeeping gene GAPDH, overcoming epigenetic silencing that has hampered stable transgenic poultry. The inserted reporter stayed active for months of cell division, proving continuous expression. This...
FDA Notification Regarding Dehydrated Alcohol
The FDA has issued a formal notice telling companies to stop distributing any dehydrated alcohol products that are not the FDA‑approved Ablysinol from Belcher Pharmaceuticals. Ablysinol, approved on June 21, 2018, is the only legally marketed dehydrated alcohol in 1 mL and 5 mL...
CMS Delays Part D Portion of BALANCE Model on Expansion of GLP-1 Access
On April 21, the Centers for Medicare & Medicaid Services announced that the Medicare Part D component of the Better Approaches to Lifestyle and Nutrition for Comprehensive Health (BALANCE) Model will be delayed until 2027 pending additional evaluation and data collection....
Washington Post Publishes AHA Letter in Response to Anti-340B Editorial
The American Hospital Association (AHA) President Rick Pollack wrote a letter to the Washington Post defending the 340B drug pricing program after an editorial called for its repeal. Pollack argues the program is vital for delivering free or low‑cost medications,...